Skip to content
Subscriber Only

Danaher Buys Cepheid for $4 Billion in First Deal Since Spinoff

  • Offer at $53 a share gives Cepheid investors 54% premium
  • Cepheid diagnostics tools test for infectious diseases
Updated on

Danaher Corp. made its first big deal since spinning off its industrial businesses in July to focus on science and technology, with the acquisition of medical diagnostics company Cepheid for $4 billion, including debt.

The offer, at $53 a share, is 54 percent higher than Cepheid’s closing price on Friday, the last day of trading since the U.S. Labor Day holiday. With the deal, Danaher Chief Executive Officer Thomas Joyce is gaining a maker of instruments that enable fast genetic testing for infectious diseases. The tools are crucial in containing the spread of highly problematic hospital-acquired bugs like MRSA and C. difficile, said Ross Muken, an analyst at Evercore ISI.